ImmunityBio, Inc. IBRX Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $44.21M+168% | $38.29M+407% | $32.06M+425% | $26.43M+2,424% | $16.52M+41,193% | ||
| $238K+310% | $382K— | $177K— | $136K— | $58K— | ||
| $43.97M+167% | $37.9M+402% | $31.88M+422% | $26.29M+2,411% | $16.46M+41,048% | ||
| 99.5%-0.2pp | 99%-1.0pp | 99.4%-0.6pp | 99.5%-0.5pp | 99.6%-0.4pp | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $114M+40.8% | $102.97M+33.8% | $87.69M+1.5% | $97.71M-2.7% | $80.95M-15.0% | ||
| -$69.79M-8.3% | -$64.68M+6.8% | -$55.63M+30.7% | -$71.29M+28.2% | -$64.43M+32.3% | ||
| -157.9%+232pp | -169%+750pp | -173.5%+1,141pp | -269.8%+9,218pp | -390.1%+237,600pp | ||
| $13.87M+2.5% | $12.3M+6.9% | $12.3M+12.6% | $13.41M+45.3% | $13.53M+69.1% | ||
| -$563M-760% | $0— | -$11.68M-112% | -$21.02M+40.4% | -$65.47M-68.2% | ||
| $2.31M+161% | $2.3M+93.6% | $2.07M+15.0% | $1.15M-39.0% | $887K-71.4% | ||
| -$632.79M-387% | -$62.09M-4.9% | -$67.31M+21.5% | -$92.31M+31.4% | -$129.9M+3.2% | ||
| $9K+104% | -$135K— | -$35K— | $269K— | -$234K— | ||
| -$632.78M-388% | -$61.94M-4.7% | -$67.25M+21.6% | -$92.56M+31.2% | -$129.65M+3.3% | ||
| -1,431.4%-647pp | -161.8%+622pp | -209.8%+1,194pp | -350.3%+12,502pp | -784.9%+334,488pp | ||
| -$0.62-313% | -$0.06+33.3% | -$0.07+50.0% | -$0.10+50.0% | -$0.15+25.0% | ||
| -$0.62-313% | -$0.06+14.3% | -$0.07+41.7% | -$0.10+50.0% | -$0.15+25.0% | ||
| 1B+20.4% | 919.9M+31.3% | 946.6M+35.6% | 888.2M+29.3% | 853.2M+26.8% | ||
| 1B+20.4% | 919.9M+31.9% | 946.6M+36.0% | 888.2M+29.3% | 853.2M+26.8% | ||
| $1.11M-80.1% | —— | $289K-82.1% | $1.93M-90.9% | $5.58M+305% | ||
| -$236.63M-456% | -$191K-100% | -$1.17M— | $0— | -$42.58M— | ||
| -$5.92M-14,332% | -$1.67M— | -$187K-1,658% | -$278K-1,535% | -$41K-105% | ||
| $44.21M+168% | $38.29M+407% | $32.06M+425% | $26.43M+2,424% | $16.52M+41,193% | ||
| -$69.79M-8.3% | -$64.68M+6.8% | -$55.63M+30.7% | -$71.29M+28.2% | -$64.43M+32.3% | ||
| -$65.41M-7.9% | -$60.82M+6.8% | -$51.68M+31.8% | -$67.41M+29.0% | -$60.6M+33.1% | ||
| -$65.41M-7.9% | -$60.82M+6.8% | -$51.68M+31.8% | -$67.41M+29.0% | -$60.6M+33.1% | ||
| -148%+219pp | -158.9%+705pp | -161.2%+1,080pp | -255.1%+8,811pp | -366.9%+226,236pp | ||
| -$69.79M-8.3% | -$64.68M+6.8% | -$55.63M+30.7% | -$71.29M+28.2% | -$64.43M+32.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is ImmunityBio, Inc.'s revenue?
- ImmunityBio, Inc. (IBRX) generated $141.0M in revenue over the trailing twelve months, up 351.5% year over year.
- Is ImmunityBio, Inc. profitable?
- ImmunityBio, Inc. is not currently profitable: it reported a net loss of $854.5M over the trailing twelve months, a -606.2% net margin.
- What are ImmunityBio, Inc.'s profit margins?
- Gross margin is 99.3% and operating margin is -185.4%, with a -606.2% net margin.
- What is ImmunityBio, Inc.'s earnings per share?
- ImmunityBio, Inc.'s diluted EPS over the trailing twelve months is $-0.85.
- Where does ImmunityBio, Inc.'s income statement data come from?
- Every line is extracted from ImmunityBio, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
